RecruitingNCT06486350

IL-6: A Marker for AML Chemo Sensitivity

Bone Marrow Supernatant IL-6 as a Predictor of Chemotherapy Sensitivity in AML Patients

Sponsor

Fujian Medical University Union Hospital

Enrollment

72 participants

Start Date

Oct 1, 2023

Study Type

OBSERVATIONAL

Conditions

AML, Adult

Summary

Acute myeloid leukemia (AML) is a clonal malignancy that arises from the primitive hematopoietic cells within the hematopoietic system. According to SEER cancer statistics, the 5-year survival rate for AML patients stands at a concerning 30%. Despite therapeutic advancements, the development of chemotherapy resistance and the risk of disease relapse pose significant barriers to curative outcomes. Evidence has linked elevated interleukin-6 (IL-6) levels in plasma and bone marrow to a poorer prognosis in AML, with IL-6 potentially fostering chemotherapy resistance through the enhancement of fatty acid uptake and the induction of stromal-like morphological changes in AML cells. However, the role of IL-6 as a potential biomarker for monitoring chemotherapy sensitivity in AML has not been fully elucidated. This study seeks to investigate the correlation between IL-6 levels in bone marrow supernatant and the sensitivity to chemotherapy, offering a clinical perspective that could pave the way for improved prognostic markers and personalized treatment strategies.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

Clinical diagnosis aligns with the "Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2023)";
All patients are experiencing their first onset of the disease and have not received any related chemotherapy prior to the study;
Patients participate in the study accompanied by family members and sign informed consent documents.

Exclusion Criteria6

Patients with concurrent malignancies requiring treatment;
Presence of infectious diseases, including SARS, viral hepatitis, or HIV/AIDS;
Major surgery performed within the last 21 days;
Performance Status (PS) score \>3;
Severe liver or kidney dysfunction or serious infection;
Severe psychiatric conditions that impair understanding of the study protocol or voluntary withdrawal.